ClinicalTrials.gg
RecruitingNCT06568094Updated Sep 17, 2026

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

A Phase 1/2 interventional study of HRS-5041 tablets and Abiraterone Acetate tablets(II) in Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 14 open to participants now, 17 under way, 4 of them phase 3. Prostatic Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
12th of 31
100 · median 69
Started
2024
with 2 others
Phase 1/2
7 of 31
5 open now
Primary completion
2026-12
later than 7 of 16 live
Registered
20th of 31
by date

Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 12th largest by planned enrollment, is one of 3 that started in 2024, is one of 7 in phase 1/2, reaches primary completion later than 7 of the 16 other live ones, and was the 20th registered.

Prostatic Neoplasms

7,047 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the ability to give , and are willing and able to comply with planned visits for medical examinations and other procedural requirements.
  2. The age is above 18 years old when signing the informed consent (the ceiling age is 80 years old in the dose escalation phase), male.
  3. score is 0 or 1.
  4. An expected survival of ≥ 12 weeks.
  5. Adenocarcinoma of the prostate confirmed with histologically or cytologically ,and without a diagnosis of neuroendocrine or small cell carcinoma.
  6. Adequate blood samples should be provided for gene mutation detection during the screening period. It is recommended to provide tumor tissue samples.
  7. Male subjects whose partner is women of (WOCBP) are required to use highly effective from the date of signing the informed consent until 3 months after the last dose of the drug.

Exclusion criteria

Exclusion Criteria:

  1. Plan to receive any other antitumor therapy during this study.
  2. Had history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML); Or had other in the 5 years prior to the first dose.
  3. Participants who are participating in another clinical study or whose first dose is less than 4 weeks from the end of the previous clinical study (last dose), or five half-lives of the drug, whichever is shorter.
  4. Had undergone major surgery within 28 days prior to first dosing; Minor traumatic surgery within 7 days prior to first dosing; There are non-healing wounds, untreated fractures.
  5. Drugs with a strong inducer or inhibitor of the metabolic enzyme have been used in the past, and the from the end time to the first administration in this study is shorter than the 5 half-life of the drug.
  6. The toxicity from previous anti-tumor treatment has not recovered to ≤ grade I.
  7. Central nervous system or meningeal of tumors is known or subjects have a history of primary central nervous system tumors.
  8. Severe cerebrovascular disease occurred within 6 months prior to administration.
  9. Subjects with poorly controlled hypertension and a history of hypertensive crisis or hypertensive encephalopathy.
  10. Severe bone injury due to bone metastases, pathological fractures , and spinal cord compression as determined by the investigators at important sites that occurred within the last 6 months or are expected to occur in the near future.
  11. Having one of multiple factors that affect the oral drug or having an active gastrointestinal disease or other disease that may significantly affect drug absorption, distribution, metabolism, or excretion.
  12. Had history of allergy to the proposed investigational drug or its components.
  13. Presence of active heart disease in the 6 months prior to first dosing, including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, and medically treatable ventricular arrhythmias.
  14. Presence of active and ; Or serious infected persons requiring antibiotics, antivirals or antifungal drugs to control.
  15. Presence of the history of immunodeficiency or organ transplantation.
  16. Presence of other serious physical or mental diseases or laboratory abnormalities.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    HRS-5041 tablets combined with Abiraterone Acetate tablets(II)and Prednisone Acetate tablets

    Drug: HRS-5041 tablets · Drug: Abiraterone Acetate tablets(II) · Drug: Prednisone Acetate tablets

  • Experimental
    HRS-5041 tablets combined with Docetaxel injection and Prednisone Acetate tablets

    Drug: HRS-5041 tablets · Drug: Prednisone Acetate tablets · Drug: Docetaxel Injection

  • Experimental
    HRS-5041 tablets combined with HRS-1167 tablets

    Drug: HRS-5041 tablets · Drug: HRS-1167 tablets

  • Experimental
    HRS-5041 tablets combined with SHR2554 tablets

    Drug: HRS-5041 tablets · Drug: SHR2554 tablets

  • Experimental
    HRS-5041 tablets combined with HRS-6208 capsules

    Drug: HRS-5041 tablets · Drug: HRS-6208 capsules

  • Experimental
    HRS-6208 capsules combined with Abiraterone Acetate tablets(II)and Prednisone Acetate tablets

    Drug: Abiraterone Acetate tablets(II) · Drug: Prednisone Acetate tablets · Drug: HRS-6208 capsules

  • Experimental
    HRS-5041 tablets combined with HRS-2189 tablets

    Drug: HRS-5041 tablets · Drug: HRS-2189 Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (Phase Ib)

    Time frame: 21 or 28 days

  2. Incidence and severity of adverse events (AE) (Phase Ib)

    Time frame: 2 years

  3. PSA response rate (Phase II)

    Time frame: 1 year

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: 1 year

  2. Disease control rate (DCR)

    Time frame: 1 year

  3. Duration of response (DoR)

    Time frame: 1 year

  4. PSA response rate

    Time frame: 1 year

  5. Time to PSA progression

    Time frame: 1 year

  6. Radiographic progression-free survival (rPFS)

    Time frame: 1 year

  7. Overall survival (OS)

    Time frame: 2 years

  8. Blood concentrations of HRS-5041(Phase Ib)

    Time frame: 16 weeks

  9. Blood concentrations of HRS-1167(Phase Ib)

    Time frame: 16 weeks

  10. Blood concentrations of SHR2554(Phase Ib)

    Time frame: 16 weeks

  11. Blood concentrations of Abiraterone (Phase Ib)

    Time frame: 16 weeks

  12. Blood concentrations of HRS-6208 (Phase Ib)

    Time frame: 16 weeks

  13. Blood concentrations of HRS-2189 (Phase Ib)

    Time frame: 16 weeks

07

Study locations

2 of 2 sites recruiting
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150000, China
    Recruiting
    • Xuedong Li · Contact
  • Shanghai Jiao Tong University School of Medicine, Renji Hospital
    Shanghai, Shanghai Municipality 200433, China
    Recruiting
    • Wei Xue · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 97 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 27 months is below that.

Counting every sponsor, half of 211 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 23, 2024
StartActual
Sep 25, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568094
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Sep 25, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Jianpo Lian
Contact
jianpo.lian.jl3@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-5041 · Prednisone acetate

Start the discussion